Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma - Trial NCT05943990
Access comprehensive clinical trial information for NCT05943990 through Pure Global AI's free database. This Phase 1 trial is sponsored by GlaxoSmithKline and is currently Terminated. The study focuses on Neoplasms. Target enrollment is 5 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 1
Dec 21, 2020
Oct 24, 2022
Primary Outcome
Number of Participants with Dose Limiting Toxicities (DLTs),Number of Participants with Adverse Events (AEs), Serious AEs and Adverse Events of Special Interest (AESI) based on Severity
Summary
To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of
 GSK3845097 in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive participants with New York
 esophageal squamous cell carcinoma (NY-ESO)-1 and/or Cancer testis antigen 2 (LAGE-1a)
 positive, previously treated, advanced (metastatic or unresectable) Synovial Sarcoma (SS) and
 Myxoid/Round Cell Liposarcoma (MRCLS).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05943990
Non-Device Trial